GlaxoSmithKline and Genmab A/S Announce European Submission to Regulatory Authorities for Arzerra® (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Published: Oct 04, 2013
Copenhagen, Denmark; October 4, 2013 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Genmab A/S (OMX: GEN) announced today the submission of a variation to the Marketing Authorization to the European Medicines Agency (EMA) for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.
Help employers find you! Check out all the jobs and post your resume.